EVO756 – Talk Bio

Actionable Insights Powered by AI

Evommune Files for IPO to Fund Phase 2 Trials of Autoimmune Drug Candidates

2 days ago talkbio0Tagged autoimmune drugs, Chronic inflammatory disorder, EVO301, EVO756, Evommune, Funding, IPO, New York Stock Exchange, Phase 2 Trials, Series C financing

Evommune; IPO; Phase 2 trials; autoimmune drugs; EVO756; EVO301; chronic inflammatory diseases; biotech funding; New York Stock Exchange; Series C financing